Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAKIH
2023-505278-13-00Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Mar 2024
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of baricitinib in hepatic adenoma (HCA), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Radiologic response of target lesion at 6 months. Planned start Mar 2024; status: authorised.
02
Drugs
baricitinib
03
Conditions
hepatic adenoma (HCA)
Beyond the preview
Go deeper on 2023-505278-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505278-13-00.